Bibliography
- LEWIS EJ, HUNSICKER LG, CLARKE WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. (2001) 345:851-860.
- BRENNER BM, COOPER ME, DE ZEEUW D et al.: Effects of losartan on renal and cardiovascular outocomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. (2001) 345:861-869.
- DE CAVANAGH EMV, INSERRA F, TOBLLI J, STELLA I, FRAGA CG, FERDER L: Enalapril attenuates oxidative stress in diabetic rats. Hypertension (2001) 38:1130-1136.
- ONOZATO ML, TOJO A, GOTO A, FUJITA T, WILCOX CS: Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int. (2002) 61:186-194.
- ICHIHARA A, HAYASHI M, KANESHIRO Y et al.: Inhibition of diabetic nephropathy by a decoy peptide corresponding to the ‘handle’ region for non-proteolytic activation of prorenin. J. Clin. Invest. (2004) 114:1128-1135.
- NGUYEN G, DELARUE F, BURCKLE C, BOUZHIR L, GILLER T, SRAER J-D: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. (2002) 109:1417-1427.
- HUANG Y, WONGAMORNTHAM S, KASTING J et al.: Renin increases mesangial cell transforming growth factor-β1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. (2006) 69(1):105-113.
- ICHIHARA A, SUZUKI F, NAKAGAWA T et al.: Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor deficient mice. J. Am. Soc. Nephrol. (2006) 17:1950-1961.
- KHAN KN, STANFIELD KM, HARRIS RK, BARON DA: Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Renal Fail. (2001) 23(3-4):321-330.
- KOMERS R, LINDSLEY JN, OYAMA TT et al.: Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J. Clin. Invest. (2001) 107(7):889-898.
- KANESHIRO Y, ICHIHARA A, TAKEMITSU T et al.: Increased expression of cyclooxygenase-2 in renal cortex of human-prorenin-receptor-gene transgenic rats. Kidney Int. (2006) 70:641-646.
- SATOFUKA S, ICHIHARA A, NAGAI N et al.: Suppression of ocular inflammation in endotoxin-induced uveitis by inhibiting nonproteolytic activation of prorenin. Invest. Ophthalmol. Vis. Sci. (2006) 47(6):2686-2692.
- OBATA J, NAKAMURA T, TAKANO H et al.: Increased gene expression of components of the renin–angiotensin system in glomeruli of genetically hypertensive rats. J. Hypertens. (2000) 18(9):1247-1255.
- ICHIHARA A, KANESHIRO Y, TAKEMITSU T et al.: Non-proteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension (2006) 47:894-900.
- VENIANT M, MENARD J, BRUNEVAL P, MORLEY S, GONZALES MF, MULLINS J: Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J. Clin. Invest. (1996) 98:1966-1970.
- ICHIHARA A, KANESHIRO Y, TAKEMITSU T et al.: Contribution of non-proteolytically activated prorenin in glomeruli to hypertensive renal damage. J. Am. Soc. Nephrol. (2006) 17(9):2495-2503.
- SUZUKI F, HAYAKAWA M, NAKAGAWA T et al.: Human prorenin has ‘gate and handle’ regions for its non-proteolytic activation. J. Biol. Chem. (2003) 278:22217-22222.
- DANSER AH, DEINUM J: Renin, prorenin and the putative (pro)renin receptor. Hypertension (2005) 46(5):1069-1076.
- NGUYEN G: Renin/prorenin receptors. Kidney Int. (2006) 69(9):1503-1506.
- DANSER AH: Prorenin: back into the arena. Hypertension (2006) 47(5):824-826.